Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lots for you today from the 2023 STAT Summit. Our podcast came live from the rollicking Boston affair, and we heard from plenty of the field’s top players. This includes Biogen CEO Chris Viehbacher, who spoke of how the company wants to move forward in a more disciplined fashion. We also talk about why Beam Therapeutics is cutting back so dramatically, and more.

The need-to-know this morning
• Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around a class of targeted chemotherapy treatments called antibody-drug conjugates. STAT reporter Drew Joseph has more details on one of the largest biopharma licensing deals in recent years.
• A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In